Everest Medicines: A Conversation on the Latest Results from the Ongoing Phase 1b/2a Clinical Trial of EVER001, a Next-Generation Covalent Reversible BTK Inhibitor for the Treatment of Primary Membranous Nephropathy (pMN)
| DATE: | June 30, 2025 |
|---|---|
| TIME: | 8:00 AM EDT |
| LOCATION: | Virtual |
About The Event
Join Everest Medicines for a virtual nephrology-focused key opinion leader (KOL) event. The event will feature:
- Richard Lafayette, MD – Professor of Medicine, Stanford University
- Ian Woo – President and Chief Financial Officer at Everest Medicines
- Sandra Zeng – Chief Medical Officer at Everest Medicines
The speakers will present an overview of pMN and the current treatment landscape in the U.S. and China, followed by a discussion of the latest data cut from the EVER001 trial as of March 21, 2025.
Everest recently presented an update on this study at the European Renal Association and reported positive preliminary results, with patient follow-up data as of December 14, 2024. Currently no drug has been approved anywhere for the treatment of pMN. There are approximately 2 million patients with pMN in China, and nearly 220,000 patients in the United States, Europe and Japan.
A live question and answer session will follow the formal presentations.
For the Chinese version, please click here.